R

Read Gene SA
WSE:RDG

Watchlist Manager
Read Gene SA
WSE:RDG
Watchlist
Price: 4.95 PLN -0.2% Market Closed
Market Cap: 58.4m PLN
Have any thoughts about
Read Gene SA?
Write Note

Read Gene SA
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Read Gene SA
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
R
Read Gene SA
WSE:RDG
Free Cash Flow
-zł716.1k
CAGR 3-Years
N/A
CAGR 5-Years
-10%
CAGR 10-Years
4%
M
Mabion SA
WSE:MAB
Free Cash Flow
zł15.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genomed SA
WSE:GEN
Free Cash Flow
zł1.8m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Free Cash Flow
zł13.2m
CAGR 3-Years
N/A
CAGR 5-Years
6%
CAGR 10-Years
N/A
U
Urteste SA
WSE:URT
Free Cash Flow
-zł7.1m
CAGR 3-Years
-72%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Free Cash Flow
-zł101.7m
CAGR 3-Years
-373%
CAGR 5-Years
N/A
CAGR 10-Years
-27%
No Stocks Found

Read Gene SA
Glance View

Market Cap
58.4m PLN
Industry
Biotechnology

Read-Gene SA engages in the medical research and testing. The company is headquartered in Szczecin, Woj. Zachodniopomorskie. The company went IPO on 2009-02-12. The company is focused on technologies which aim is to detect, prevent and treat malignant tumors. The firm specializes in three fields: chemoprevention, clinical trials and genetic testing. The company offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The firm operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.

RDG Intrinsic Value
2.52 PLN
Overvaluation 49%
Intrinsic Value
Price
R

See Also

What is Read Gene SA's Free Cash Flow?
Free Cash Flow
-716.1k PLN

Based on the financial report for Jun 30, 2024, Read Gene SA's Free Cash Flow amounts to -716.1k PLN.

What is Read Gene SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
4%

Back to Top